CML cells exposed to bortezomib leads to conformational changes in Bax protein, resulting in loss of mitochondrial membrane potential and leakage of cytochrome c to the cytosol. Here, BAX is linked to chronic myelogenous leukemia, BCR-ABL1 positive.